Biocon Limited has announced the appointment of Shreehas Tambe as Chief Executive Officer and Managing Director, effective April 1, 2026. The decision follows approvals from the company’s Nomination and Remuneration Committee and Board of Directors. This leadership transition comes as Biocon completes the integration of Biocon Biologics as a wholly owned subsidiary, creating a unified organizational structure.
As the first CEO of the integrated entity, Mr Tambe will lead a combined platform encompassing biosimilars and generics. The move is expected to strengthen Biocon’s global competitiveness and enhance its ability to scale operations across key therapeutic areas including diabetes, oncology, immunology, and obesity.
Kiran Mazumdar-Shaw, Executive Chairperson of Biocon, said the integration marks a significant milestone in the company’s evolution into a globally scaled biopharmaceutical enterprise. She noted that Mr Tambe has played a central role in advancing Biocon’s strategic initiatives, including the acquisition and integration of the Viatris biosimilars business and expansion into international markets. Under his leadership, Biocon Biologics has grown into one of the world’s leading biosimilar companies.
Mr Tambe expressed his commitment to advancing Biocon’s mission of improving access to affordable healthcare worldwide. He emphasized the importance of strengthening operational foundations, consolidating business lines, and driving sustainable growth as the company expands its global footprint.
With nearly three decades at Biocon, Mr Tambe has held several leadership roles across research, operations, and global business development. He has contributed to the expansion of the company’s insulin portfolio and played a key role in establishing large-scale manufacturing capabilities, including a major insulin facility in Malaysia. He is also an inventor on multiple patents, reflecting his strong background in scientific innovation.
As part of the leadership changes, Kedar Upadhye has been appointed Chief Financial Officer. Meanwhile, Siddharth Mittal will transition to another role within the Biocon Group after serving in senior leadership positions for over a decade.
Biocon continues to build on its integrated model that combines research, manufacturing, and commercialization. The company operates in more than 120 countries, supported by a diversified portfolio of biosimilars and generic medicines, and remains focused on addressing critical healthcare needs globally.
